GSK stock trades at GBp 1,779.50 after Nuvalent deal risks emerge

Published on 10/04/2026 at 11:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK reported Q2 2026 turnover of GBP 8.4 billion, up 5 percent year over year. A 23-analyst consensus shows Outperform and a GBP 21.71 average target.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) was last quoted at GBp 1,779.50 on the London Stock Exchange on October 2, 2026, down 0.86 percent for the session. The stock sits 22.0 percent below its 52-week high of GBp 2,282.00, giving the pipeline and acquisition strategy a demanding market backdrop.

Q2 turnover reaches GBP 8.4 billion

Moomoo reports that GSK generated GBP 8.4 billion of turnover in Q2 2026, up 5 percent year over year, while first-half sales reached GBP 16.0 billion, up 3 percent on an AER basis and 5 percent at constant exchange rates. Core EPS rose to GBp 50.5 from GBp 46.5 in Q2 2025.

The comparison is mixed beneath the revenue growth. Total EPS fell to GBp 10.8 from GBp 35.5 because GSK booked GBP 1.9 billion of intangible impairments, including GBP 1.3 billion linked to camlipixant.

Nuvalent adds USD 10.6 billion oncology bet

GSK agreed to acquire oncology specialist Nuvalent for USD 10.6 billion, according to Halifax. The transaction adds three lung-cancer assets, including two late-stage inhibitors, but regulatory approval remains central to the investment case.

The same report says GSK reaffirmed 2026 guidance for 7 percent to 9 percent core operating profit and core EPS growth. Management also expects the acquisition to contribute to revenue growth from 2027 and support the business through the dolutegravir loss-of-exclusivity period from 2028 to 2030.

Analysts see GBP 21.71 target

A MarketScreener consensus published September 15, 2026, rates GSK Outperform across 23 analysts and gives an average target of GBP 21.71. Berenberg upgraded the stock to Buy and raised its target from USD 54 to USD 60 on the same date.

The next dated checkpoint is Q3 reporting. Stock Analysis lists October 28, 2026, as the next confirmed earnings date, before the market opens.

GSK stock stays below yearly high

GSK stock was last at GBp 1,779.50 on October 2, 2026, with a session range of GBp 1,770.00 to GBp 1,802.00 and volume of 5,390,000 shares. Its 52-week range is GBp 1,592.00 to GBp 2,282.00.